Morgan Stanley initiates Waystar stock coverage with Equalweight rating By Investing.com

Waystar reported Q4 revenue and EBITDA beats of +3.0% and +6.9%, with LTM revenue growth of 16.5% and EBITDA of $392M; Morgan Stanley initiated coverage at Equalweight with a $28 price target while the stock trades at $23.54 (down ~38% over the past year). Morgan Stanley's $28 PT is based on a 10.5x EV/EBITDA on 2027 estimates; the stock's trailing EV/EBITDA is ~15.1x. Multiple brokers cut price targets citing AI uncertainty (BMO $30 from $47, TD Cowen $42 from $54, Jefferies $41 from $43, Truist $38 from $51) while BofA and others remain positive on the Google Cloud/Gemini collaboration. Overall, fundamentals show modest upside but analyst views are mixed due to AI disruption risk and valuation debate.

Analysis

The market is treating AI exposure as binary rather than gradual: winners will not simply be vendors that 'have AI' but those that can convert AI into measurable ARPU uplifts and materially lower cost-to-collect. That advantages vendors with deep payer connections, large installed bases and cloud partnerships that limit implementation friction, while it punishes point solutions that promise scribes but lack data plumbing or certified cloud integrations.

Second-order winners include hyperscalers (cloud compute and MLOps), enterprise SI partners and cybersecurity firms that monetize HIPAA-grade deployments; losers are small independent RCM outfits and niche scribe vendors that face rapid margin pressure and higher customer churn. Regulatory and privacy frictions create a multi-quarter adoption runway — the risk horizon for disruptive LLM substitution is months-to-years, not weeks, giving time for incumbents to monetize AI defensively.

Catalysts that will move the stock materially are (1) verifiable customer-level ARPU or margin lift tied to AI pilots, (2) multi-quarter guidance upgrades showing secular cross-sell acceleration, and (3) an M&A or strategic JV that crystallizes strategic value. The principal tail risk is faster-than-expected commoditization of front-end workflows by large LLM vendors or open-source projects, which would compress pricing across the RCM stack and force volume-driven renewals.

A contrarian read is that the sell-side is overweighing theoretical AI threat while underappreciating integration friction and switching costs; cloud-native partnerships raise the bar for new entrants and create a path to sustainably higher gross margins if cross-sell converts. Time the exposure to evidence of commercial traction — 2–4 named customer wins or 2 consecutive quarters of above-consensus SaaS ARPU growth should flip the risk/reward materially in favor of the long case.

Key Decisions for Investors

• Long directional (12–18 month): Buy a calendar call spread on WAY (9–12 month near-term calls + sell further-dated calls) sized to 2–4% fund exposure to capture a re-rate if 3–4 quarters of AI-driven ARPU/margin proofs arrive; defined debit limits downside to premium paid, upside asymmetry ~2–4x if market re-rates to healthcare IT peers.
• Pair trade (12 months): Long WAY vs short RCM (R1, ticker RCM) equal notional — hedge macro/sector beta and isolate re-rating/cross-sell execution. Rationale: WAY benefits more from cloud/partnership-driven stickiness while R1 is more exposed to commoditization; target >30% relative outperformance to close, stop if both companies report synchronous guidance misses.
• Event hedge (0–6 months): Purchase 3–6 month protective puts for 30% of long equity position ahead of next two earnings/partnership milestones to cap downside from an AI narrative-driven selloff; cost is insurance vs binary downside from negative AI headlines or guidance cuts.
• Opportunistic catalyst trade (6–24 months): Accumulate size on confirmed customer wins or clear synergy metrics (Iodine cross-sell >X% of base) and consider selling 12–18 month covered calls to monetize time value while holding core exposure — target rolling to higher strikes on each de-risking milestone.